Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic
- Conditions
- HIVPremature Aging
- Registration Number
- NCT03542786
- Lead Sponsor
- AB Biotics, SA
- Brief Summary
The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).
- Detailed Description
It's been demonstrated that the HIV-1 virus is associated to the reduction of the microbiota. Some studies suggest that because of this bacterial reduction, the premature aging appears. So this study aims to demonstrate that our probiotic can balance the microbiota as a preventive solution for the inflammaging.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 89
- Older than 18 years old.
- Documented HIV-1 infection.
- Be in treatment with these antiretrovirals (INI, IP, ITINAN) during 12 months.
- HIV-1 Viral titer <50 copies/mL during 6 months.
- CD4> 500 cells/mm3.
- Treatment with antibiotics.
- Severe diseases actives.
- Defining diseases of AIDS in the previous year.
- Gut surgery except appendectomy or cholecystectomy.
- Pregnancy.
- Any diet deviation (vegans).
- Other probiotic treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The appearance of adverse effects. Change from Baseline Adverse Effects will be measured at 1 month and 3 months after the treatment beginning (V1 and V2 respectively). Percentage of patients with adverse events (AE) in the 3 study arms: i3.1, i3.1 + ProSeed and Placebo.
- Secondary Outcome Measures
Name Time Method Gut microbiota diversity and metabolomic profile A measure will be made in V1, V2, V3 and V4 (1 month, 3 months, 6 months and 9 months after the treatment beginning, respectively). Biodiversity changes among the basal visit and 3 months after (in each arm), measured using the Shannon Index.
CD4/CD8 ratio A measure will be made in V2, V3 and V4 (3 months, 6 months and 9 months after the treatment beginning, respectively). Ratio changes among the basal visit and 3 months after, in each arm.
Satisfaction with the product A measure will be made in V2, V3 and V4 (3 months, 6 months and 9 months after the treatment beginning, respectively). This parameter will be measured in order to evaluate the satisfaction of the patient with the research product. The satisfaction with the product wil be measured with the Likert Scale (with answers from satisfied to unsatisfied).
Questionaire to evaluate the life quality A measure will be made in V2, V3 and V4 (3 months, 6 months and 9 months after the treatment beginning, respectively). This parameter will be measured with the Medical Outcomes Study-HIV questionaire (with answers from not affected to affected).
Questionaires to evaluate the anxiety and depression A measure will be made in V2, V3 and V4 (3 months, 6 months and 9 months after the treatment beginning, respectively). This parameter will be measured with the Hospital Anxiety Depression Scale (HADS) questionaire (with answers from never to always).
Translocational bacterial markers & Systemic inflammation markers A measure will be made in V1 and V2 (1 month and 3 months after the treatment beginning, respectively). Markers changes among the basal visit and 3 months after, in each arm.The plasma levels of lipopolysaccharide, sCD14, Interleukin 6 and Iinterleukin 10 will be measured.
Cluster of Differentation 4 (CD4) count A measure will be made in V2, V3 and V4 (3 months, 6 months and 9 months after the treatment beginning, respectively). Recount changes (cells/mm3) among the basal visit and 3 months after, in each arm.
Trial Locations
- Locations (1)
Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital Germans Trias i Pujol🇪🇸Badalona, Barcelona, Spain